Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration

Xihong Zhang, Min Lin, Kenneth L. Van Golen, Kiyoko Yoshioka, Kazuyuki Itoh, Douglas Yee

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalBreast Cancer Research and Treatment
Volume93
Issue number2
DOIs
StatePublished - Sep 1 2005

Fingerprint

Insulin-Like Growth Factor I
Cell Movement
Breast Neoplasms
Focal Adhesion Protein-Tyrosine Kinases
IGF Type 1 Receptor
Focal Adhesions
Phosphotransferases
rho-Associated Kinases
p38 Mitogen-Activated Protein Kinases
Integrins
Ligation
Phosphorylation
Phenotype
Cell Line

Keywords

  • Breast neoplasms
  • Cell motility
  • Focal adhesion kinase
  • Insulin-like growth factor-I
  • Mitogen activated protein kinase
  • Rho
  • Type I IGF receptor

Cite this

Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. / Zhang, Xihong; Lin, Min; Van Golen, Kenneth L.; Yoshioka, Kiyoko; Itoh, Kazuyuki; Yee, Douglas.

In: Breast Cancer Research and Treatment, Vol. 93, No. 2, 01.09.2005, p. 159-168.

Research output: Contribution to journalArticle

@article{1399bd16f40145b4848f87b53ece2873,
title = "Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration",
abstract = "In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.",
keywords = "Breast neoplasms, Cell motility, Focal adhesion kinase, Insulin-like growth factor-I, Mitogen activated protein kinase, Rho, Type I IGF receptor",
author = "Xihong Zhang and Min Lin and {Van Golen}, {Kenneth L.} and Kiyoko Yoshioka and Kazuyuki Itoh and Douglas Yee",
year = "2005",
month = "9",
day = "1",
doi = "10.1007/s10549-005-4626-8",
language = "English (US)",
volume = "93",
pages = "159--168",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration

AU - Zhang, Xihong

AU - Lin, Min

AU - Van Golen, Kenneth L.

AU - Yoshioka, Kiyoko

AU - Itoh, Kazuyuki

AU - Yee, Douglas

PY - 2005/9/1

Y1 - 2005/9/1

N2 - In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.

AB - In order to display the full metastatic phenotype, the cancer cell must acquire the ability to migrate. In breast cancer, we have previously shown that insulin-like growth factor I (IGF-I) enhances cell motility in the highly metastatic MDA-231BO cell line by activating the type I IGF receptor (IGF1R). This motility response requires activation of IRS-2 and integrin ligation. In order to identify the key molecules downstream of IRS-2, we examined several signaling pathways known to be involved in cell motility. Focal adhesion kinase (FAK) was not activated by IGF-I, but IGF-I caused redistribution of FAK away from focal adhesion plaques. IGF-I treatment of MDA-231BO cells activated RhoA and inhibition of Rho-kinase (ROCK) inhibited the IGF-mediated motility response. The mitogen activated protein kinase (MAPK), p38, was also activated by IGF-I and inhibition of p38 by SB203580 blocked IGF-I induced cell motility. ROCK inhibition with Y-27632 also inhibited p38 phosphorylation suggesting that p38 lies downstream of ROCK. Both Erk1,2 and phosphatidyl-3 kinase (PI3K) were required for IGF-I stimulated cell motility, but only PI3K appeared to be directly downstream of IGF-I. Thus, IGF-I activation of its receptor coordinates multiple signaling pathways required for cell motility. Defining the key molecules downstream of the type I IGF receptor may provide a basis for optimizing therapies directed at this target.

KW - Breast neoplasms

KW - Cell motility

KW - Focal adhesion kinase

KW - Insulin-like growth factor-I

KW - Mitogen activated protein kinase

KW - Rho

KW - Type I IGF receptor

UR - http://www.scopus.com/inward/record.url?scp=25844465843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844465843&partnerID=8YFLogxK

U2 - 10.1007/s10549-005-4626-8

DO - 10.1007/s10549-005-4626-8

M3 - Article

C2 - 16187236

AN - SCOPUS:25844465843

VL - 93

SP - 159

EP - 168

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -